BioStock Studio: Scandion Oncology pushes forward with confidence

29 June 2020 - 08:21

Scandion Oncology has been very active of late, which has had significant effect on the company share. BioStock was happy to welcome CEO Nils Brünner back to the BioStock studio to give us some background about the company and discuss what makes Scandion Oncology an attractive investment.  

Watch the video interview with Scandion Oncology's CEO Nils Brünner at

This is a press release from BioStock - Connecting Innovation & Capital.

Provided by: Cision
Spotlight (Sweden)
Scandion Oncology A/S
Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date